Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi Trials

Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cuneo, Antonio

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting

N/A

319

Europe

Ropeginterferon alfa-2b, Besremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Polycythemia Vera

09/26

12/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

NCT05393024: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Completed

N/A

Europe

Belantamab mafodotin

Fondazione EMN Italy Onlus

Multiple Myeloma

08/24

Rigolin, Gian Matteo

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting

N/A

4000

Europe

Registration into the STREAM platform

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/32

CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

N/A

520

Europe

Quality of life questionnaires

Gruppo Italiano Malattie EMatologiche dell'Adulto

Multiple Myeloma

12/24

CICCONE, Maria

NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting

414

Europe

Gemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.

Acute Myeloid Leukemia

04/25

04/27

1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting

N/A

343

Europe, RoW

Questionnaire

Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC

Acute Myeloid Leukemia

06/21

12/22

Cavazzini, Francesco

MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

	Jan 2024 - Dec 2024: Approval for myelofibrosis
	Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
	Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
	Feb 2024 - Feb 2024: Completion of P2b trial for JIA
	Feb 2024 - Feb 2024: Exclusivity expiry in US

Active, not recruiting

430

Europe, Canada, US, RoW

Pelabresib, Ruxolitinib, Placebo

Constellation Pharmaceuticals

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

08/23

12/27

PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Completed

N/A

1150

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Polycythemia Vera

12/23

RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting

N/A

1055

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis

05/32

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

Formigaro, Luca

No trials found

Lista, Enrico

No trials found

Cueno, Antonio

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cuneo, Antonio

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

Chronic Lymphoid Leukemia

09/27

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting

N/A

319

Europe

Ropeginterferon alfa-2b, Besremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Polycythemia Vera

09/26

12/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

NCT05393024: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Completed

N/A

Europe

Belantamab mafodotin

Fondazione EMN Italy Onlus

Multiple Myeloma

08/24

Rigolin, Gian Matteo

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting

N/A

4000

Europe

Registration into the STREAM platform

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/32

CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

N/A

520

Europe

Quality of life questionnaires

Gruppo Italiano Malattie EMatologiche dell'Adulto

Multiple Myeloma

12/24

CICCONE, Maria

NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting

414

Europe

Gemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.

Acute Myeloid Leukemia

04/25

04/27

1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting

N/A

343

Europe, RoW

Questionnaire

Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC

Acute Myeloid Leukemia

06/21

12/22

Cavazzini, Francesco

MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

	Jan 2024 - Dec 2024: Approval for myelofibrosis
	Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
	Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
	Feb 2024 - Feb 2024: Completion of P2b trial for JIA
	Feb 2024 - Feb 2024: Exclusivity expiry in US

Active, not recruiting

430

Europe, Canada, US, RoW

Pelabresib, Ruxolitinib, Placebo

Constellation Pharmaceuticals

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

08/23

12/27

PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Completed

N/A

1150

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Polycythemia Vera

12/23

RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting

N/A

1055

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis

05/32

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

Formigaro, Luca

No trials found

Lista, Enrico

No trials found

Cueno, Antonio

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites